4.0
Boston Scientific Corporation is a United States–based company operating in the healthcare sector, within the medical-device industry.
The company specializes in the development, manufacturing and commercialization of minimally invasive technologies used to diagnose and treat cardiovascular, neurological, urological, gastrointestinal and various other medical conditions.
Founded in 1979 in Massachusetts by John Abele and Pete Nicholas, the company emerged during a period of rapid innovation in interventional medicine, motivated by the need to provide safer alternatives to traditional surgical procedures.
Boston Scientific’s portfolio includes coronary and peripheral stents, ablation catheters, electrophysiology tools, implantable devices for arrhythmia management, peripheral-intervention systems, neuromodulation implants, spinal cord stimulators, endoscopy devices, women’s health solutions, urology tools and technologies for chronic-pain treatment.
The company also works on advanced areas such as digital health platforms, image-guided therapies and smart implantable systems. The company operates globally across North America, Europe, Asia-Pacific, Latin America and the Middle East.
Its operational structure includes research and development centers, manufacturing facilities, biomedical engineering laboratories, regional scientific teams, hospital-distribution networks and clinical-support groups.
Boston Scientific collaborates with hospitals, universities and research institutions to design technologies that support modern interventional procedures.
Market factors affecting its performance include demographic aging, rising incidence of cardiovascular and neurological diseases, advancement of minimally invasive therapies, regulatory requirements, healthcare reimbursement dynamics, competition within the medical-device industry and growing demand for high-precision clinical solutions.
The company also monitors trends in digitalization, data-driven care and personalized therapeutic technologies.
Boston Scientific Corporation’s shares trade on the New York Stock Exchange (NYSE) under the ticker BSX.
History and when Boston Scientific Corporation was founded
Boston Scientific was founded in 1979 by John Abele and Pete Nicholas with the objective of expanding access to minimally invasive therapies. In its early years, the company focused on catheter-based devices used in interventional cardiology and radiology.
A key step in its early growth was the acquisition of Medi-Tech, which specialized in angiographic and catheter-based technologies, enabling Boston Scientific to expand into additional clinical areas.
Throughout the 1980s and 1990s, the company grew steadily alongside the rise of interventional cardiology. A milestone occurred in 1992 with its initial public offering (IPO) on the New York Stock Exchange, enabling international expansion, increased R&D investment and strategic acquisitions.
During this period, Boston Scientific strengthened its presence in Europe and Asia and broadened its cardiovascular capabilities. In the 2000s, the company executed major acquisitions to diversify its product portfolio, most notably the 2006 acquisition of Guidant Corporation.
This transaction expanded its footprint in electrophysiology, cardiovascular devices and implantable arrhythmia therapies and represented one of the most significant events in the company’s history. The firm also increased its presence in endoscopy, urology and chronic-pain treatment.
From 2010 onward, Boston Scientific invested heavily in neuromodulation, structural-heart therapies and image-guided procedures. It modernized manufacturing operations, expanded digital-health initiatives and pursued targeted acquisitions to strengthen strategic clinical segments.
Between 2020 and 2024, the company navigated regulatory shifts, evolving hospital demand and supply-chain challenges.
During this period, Boston Scientific expanded cardiovascular offerings, advanced neuromodulation technologies, strengthened global operations and maintained its leadership position in the medical-devices sector through innovation and operational discipline.
Additional Information
The Company Boston Scientific Corp. (United States), is listed on NYSE with a market value of $ 144.70 Billions, having an equity of $ -.
With a total of 36.000 employees, the company is listed in the sector of Health and categorized in industry of Medical Supplies and Equipment.
In the last 12 months the Company had a revenue of $ 19.35 Billions, which generated a profit in the amount of $ 2.79 Billions.
As for its main indicators, the Company has a P/E ratio of 51.83, a P/BV ratio of 0.00 and in the last 12 months the Company did not pay dividends.
The Company is traded internationally through the ticker BSX.
